EBioMedicine · 2026
The therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Youngeun, Lee Hee-Young, Lim Hye Seong, Shin Jin A, Yang Hyun Gul, Lee Saseong, Mercadante Grazia, Cicatiello Valeria, De Falco Sandro, Kim Hyungmin, Kim Chaerin, Lee Su-Hyun, Kim Yu-Mi, Yoo Seung-Ah, Lee Seung-Hyo, Kim Wan-Uk
Аннотация
BACKGROUND: Placental growth factor (PlGF) plays a crucial role in the pathogenesis of autoimmune diseases, including rheumatoid arthritis (RA) and multiple sclerosis (MS), by enhancing angiogenesis, disease-aggravating features of fibroblast-like synoviocytes (FLSs), and pathogenic T helper type 17 (Th17) cells. The therapeutic potential of a VEGF decoy receptor fusion protein, VEGF-Grab, which potently binds and neutralises VEGF and PlGF, has not been studied in autoimmune diseases. Therefore, we investigated the therapeutic effects of VEGF-Grab in RA and MS by using in vitro and in vivo models.
METHODS: Two forms of VEGF-Grab (PB101 and PB102) were engineered to enhance their binding affinity for VEGF and PlGF. In vitro assays-including Transwell migration and wound-healing assays of endothelial cells and FLSs, as well as Th17 cell differentiation-were employed to evaluate the effects of VEGF-Grab on angiogenesis and immune-cell function. To assess therapeutic efficacy in vivo, mouse models of inflammatory and autoimmune arthritis, as well as experimental autoimmune encephalomyelitis (EAE), were utilised.
FINDINGS: Our results indicate that VEGF-Grab exerted significant inhibitory effects across various animal models of autoimmune diseases, targeting abnormal angiogenesis, cartilage invasion, and pathogenic Th17 cells. Furthermore, combined treatment with IFN-β in the EAE model suggested enhanced efficacy of therapeutic effects.
INTERPRETATION: Our findings highlight the multifaceted therapeutic potential of VEGF-Grab in RA and MS, targeting angiogenesis, the aggressiveness of FLSs, and the pathogenicity of Th17 cells, all driven by the 'angio-lymphokine', PlGF. Thus, VEGF-Grab has the potential to be a therapeutic candidate for the treatment of RA and MS, warranting further clinical exploration.
FUNDING: This study was supported by grants funded by the National Research Foundation of Korea (RS-2024-00442793 to W.U.K.), and Biomlogic/GenoFocus and Panolos Biosciences (to S.H.L.).
METHODS: Two forms of VEGF-Grab (PB101 and PB102) were engineered to enhance their binding affinity for VEGF and PlGF. In vitro assays-including Transwell migration and wound-healing assays of endothelial cells and FLSs, as well as Th17 cell differentiation-were employed to evaluate the effects of VEGF-Grab on angiogenesis and immune-cell function. To assess therapeutic efficacy in vivo, mouse models of inflammatory and autoimmune arthritis, as well as experimental autoimmune encephalomyelitis (EAE), were utilised.
FINDINGS: Our results indicate that VEGF-Grab exerted significant inhibitory effects across various animal models of autoimmune diseases, targeting abnormal angiogenesis, cartilage invasion, and pathogenic Th17 cells. Furthermore, combined treatment with IFN-β in the EAE model suggested enhanced efficacy of therapeutic effects.
INTERPRETATION: Our findings highlight the multifaceted therapeutic potential of VEGF-Grab in RA and MS, targeting angiogenesis, the aggressiveness of FLSs, and the pathogenicity of Th17 cells, all driven by the 'angio-lymphokine', PlGF. Thus, VEGF-Grab has the potential to be a therapeutic candidate for the treatment of RA and MS, warranting further clinical exploration.
FUNDING: This study was supported by grants funded by the National Research Foundation of Korea (RS-2024-00442793 to W.U.K.), and Biomlogic/GenoFocus and Panolos Biosciences (to S.H.L.).